CurrentBlue Cross Blue Shield - New MexicoPolicy CPCPLAB038

Urinary Tumor Markers for Bladder Cancer

Defines BCBSNM reimbursement stance for urinary biomarkers and immunocytology used to detect or monitor bladder cancer; applies to providers submitting claims to Blue Cross and Blue Shield of New Mexico.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyUrinary Tumor Markers for Bladder Cancer

Policy CodePolicy CPCPLAB038

Change TypeAdded CPT/HCPCS codes and literature review

Effective DateAug 8, 2025

Next Review Date

Key ActionProviders must submit accurate documentation and use valid code combinations when submitting claims.

SourceLink

POLICY UPDATE CHANGES

Added code 0452U.

Added code 0549U.

Added codes 0420U and 0465U.

Document updated with literature review.

4reimbursement scenarios

multipleliterature references

1.0policy version

updateshistory entries

Reimbursement and Coverage Criteria

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyUrinary Tumor Markers for Bladder Cancer

Policy CodePolicy CPCPLAB038

Change TypeAdded CPT/HCPCS codes and literature review

Effective DateAug 8, 2025

Next Review Date

Key ActionProviders must submit accurate documentation and use valid code combinations when submitting claims.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ANY of the following

ALL of the following
- Urinary biomarkers: bladder tumor antigen (BTA), nuclear matrix protein (NMP22), or UroVysion FISH may be reimbursable as an adjunct to exclude bladder cancer for individuals with atypical or equivocal cytology.
ALL of the following
- Urinary biomarkers: BTA, NMP22, or UroVysion FISH may be reimbursable as an adjunct in the monitoring of high-risk, non-muscle invasive bladder cancer.
ALL of the following
- Fluorescence immunocytology (ImmunoCyt/uCyt) may be reimbursable as an adjunct to cystoscopy or cytology in the monitoring of individuals with bladder cancer.

ALL of the following

ANY of the following
- Urinary biomarkers: bladder tumor antigen (BTA), NMP22, or UroVysion FISH are not reimbursable for these indications.
- Fluorescence immunocytology (ImmunoCyt/uCyt) is not reimbursable for these indications.

ALL of the following

Any other urinary tumor markers for bladder cancer not specifically mentioned above are not reimbursable.

Procedure Codes and Coding Notes

Newly added CPT CodesCPT

0452U	Code added to policy (specific test not detailed in body)
0549U	Code added to policy (specific test not detailed in body)
0420U	Code added to policy (specific test not detailed in body)
0465U	Code added to policy (specific test not detailed in body)

Coding — Code list completeness

Scope of code listThe procedure code list is not an all-encompassing list; inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Implication for billingProviders should not assume coverage solely because a code appears on the list; verify coverage via plan documents and contracts.

Code maintenanceCode lists may be updated; recently added codes are documented in the policy update history.

Documentation and Claims Submission

Documentation Required

Submit accurate documentation and use valid code combinations; claims may be reviewed

Providers must submit accurate documentation of services performed and submit claims using valid code combinations from HIPAA-approved code sets, coded according to industry-standard coding guidelines (for example, UB, AMA CPT, HCPCS, ICD-10, NDC, DRG, CMS NCCI). Claims are subject to code edit protocols and may be reviewed against plan documents, provider contract language, medical policies, clinical payment and coding policies, and coding software logic; providers should be prepared to submit additional documentation upon request.

Submit claims using valid code combinations from HIPAA‑approved code sets and industry coding guidelines (CPT, HCPCS, ICD‑10, UB, NDC, DRG, CMS NCCI, etc.).
Claims are subject to code edit protocols and review against plan documents, provider contracts, medical policies, CPCPs, and coding software logic.
Upon request, submit any additional documentation to support the claim.

Definitions and Referenced Tests

Definitions — Plan documents and provider contracts

Governing documentsIf a conflict arises between this Clinical Payment and Coding Policy and any plan document, the plan document will govern.

Provider contract precedenceIf a conflict arises between this CPCP and a provider contract, the provider contract will govern.

BCBSNM discretionBlue Cross and Blue Shield of New Mexico may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case; BCBSNM has full and final discretionary authority as provided under applicable plan documents.

Definitions — Urinary biomarkers referenced

BTA (bladder tumor antigen)Referenced as a urinary biomarker that may be reimbursable as an adjunct in specific diagnostic or monitoring situations.

NMP22 (nuclear matrix protein 22)Referenced as a urinary biomarker that may be reimbursable as an adjunct in specific diagnostic or monitoring situations.

UroVysion FISH (fluorescence in situ hybridization)Referenced as a urinary biomarker that may be reimbursable as an adjunct in specific diagnostic or monitoring situations.

ImmunoCyt/uCyt (fluorescence immunocytology)Referenced as a fluorescence immunocytology test that may be reimbursable as an adjunct to cystoscopy or cytology for monitoring individuals with bladder cancer.